SJ 04
Alternative Names: SJ-04Latest Information Update: 15 Oct 2024
At a glance
- Originator Shanghai Bao Pharmaceuticals
- Class Infertility therapies; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Infertility
Most Recent Events
- 01 Oct 2024 Suzhou Centergene Pharmaceuticals plans a phase I comparative immunogenicity and pharmacokinetics trial in Healthy subjects in China (SC, Injection) (NCT06599528)
- 15 Mar 2022 Preclinical trials in Infertility in China (Parenteral) (Shanghai Bao Pharmaceuticals pipeline, March 2022).